Company intelligence / Profile preview

Topokine Therapeutics

Ownership: Private
Development stage: Other

Overview

Topokine’s lead asset, XAF5 Ointment, was in late-stage clinical development for the reduction of undereye bags. In a Phase 2 randomized controlled trial, XAF5 met its primary endpoint with statistically significant and clinically meaningful reductions in undereye bags. A pivotal Phase 2b/3 study was initiated in January 2016. The second program, TAT4 Gel for nasolabial folds, entered Phase 2 trials. The company’s assets were protected by over 75 issued and pending patents worldwide.

Therapeutic areas: Dermatology
Modalities: Topical small molecules (adipomodulatory medicines)
Industry: Biotech

Partnerships

No major external partnerships disclosed prior to acquisition.

Beyond the preview

Go deeper on Topokine Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Topokine Therapeutics.